Birajdar Swapnali Vasant, Mazahir Farhan, Yadav Awesh K
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.
Drug Dev Ind Pharm. 2023 Dec;49(12):734-747. doi: 10.1080/03639045.2023.2282990. Epub 2023 Dec 20.
We report the preparation, characterization, and therapeutic evaluation of Metformin-Loaded, Transferrin-Poloxamer-Functionalized Chitosan Nanoparticles (TPMC-NPs) for their repurposing in Alzheimer's disease (AD).
Usefulness of this work to establish the repurposing of metformin for the treatment of AD.
The TPMC-NPs were prepared by ionic gelation method using sodium tripolyphosphate. The modification and functionalization were confirmed by FTIR and HNMR spectroscopy. The physicochemical characterization was performed using DLS, FTIR,H-NMR, CD spectroscopy, SEM, DSC, PXRD, HR-TEM, and hot-stage microscopy.
The size, PDI, percent entrapment efficiency, and percent drug loading of TPMC-NPs were found to be 287.4 ± 9.5, 0.273 ± 0.067, 81.15 ± 7.17%, 11.75%±8.21%, respectively. Electron microscope analysis revealed smooth and spherical morphology. The transferrin conjugation efficiency was found to be 46% by the BCA method. loss of the secondary structure of transferrin after conjugation. PXRD data indicated the amorphous nature of the TPMC-NPs. Hot-stage microscopy and DSC confirmed the thermal stability of TPMC-NPs. The drug release showed a sustained release at pH 7.4. The DPPH assay displayed 80% antioxidant activity of TPMC-NPs in comparison with metformin and blank NPs. The cytotoxicity assay revealed 69.60% viable SH- SY5Y cells at 100 µg/mL of TPMC NPs. The nasal ciliotoxicity and mucoadhesion studies showed no significant toxicity, and 98.16% adhesion, respectively. The nasal permeability study showed the release of metformin within 30 min from TPMC-NPs.
The obtained results suggested the usefulness of TPMC-NPs in the treatment of AD the intranasal route.
我们报告了载有二甲双胍、转铁蛋白 - 泊洛沙姆功能化壳聚糖纳米颗粒(TPMC - NPs)的制备、表征及治疗评估,以用于其在阿尔茨海默病(AD)中的重新应用。
这项工作对于确立二甲双胍重新用于治疗AD的实用性。
采用三聚磷酸钠通过离子凝胶法制备TPMC - NPs。通过傅里叶变换红外光谱(FTIR)和核磁共振氢谱(HNMR)光谱确认修饰和功能化。使用动态光散射(DLS)、FTIR、H - NMR、圆二色光谱(CD)、扫描电子显微镜(SEM)、差示扫描量热法(DSC)、粉末X射线衍射(PXRD)、高分辨率透射电子显微镜(HR - TEM)和热台显微镜进行物理化学表征。
TPMC - NPs的粒径、多分散指数(PDI)、包封率百分比和载药量百分比分别为287.4±9.5、0.273±0.067、81.15±7.17%、11.75%±8.21%。电子显微镜分析显示出光滑的球形形态。通过BCA法发现转铁蛋白偶联效率为46%。偶联后转铁蛋白二级结构丧失。PXRD数据表明TPMC - NPs为无定形性质。热台显微镜和DSC证实了TPMC - NPs的热稳定性。药物释放在pH 7.4时呈现持续释放。与二甲双胍和空白纳米颗粒相比,DPPH测定显示TPMC - NPs具有80%的抗氧化活性。细胞毒性测定显示在100μg/mL的TPMC纳米颗粒下有69.60%的SH - SY5Y细胞存活。鼻纤毛毒性和黏膜粘附研究分别显示无明显毒性和98.16%的粘附率。鼻通透性研究表明二甲双胍在30分钟内从TPMC - NPs中释放。
所得结果表明TPMC - NPs通过鼻内途径治疗AD具有实用性。